Immune Checkpoint Binding and Interaction Assays

The immune checkpoint inhibitors perform their functions through blocking interactions between immune checkpoint protein and ligand. Creative Biolabs has accumulated rich experience in immune checkpoint assays development for many years. Armed with our established technology platform, we can offer a full range of immune checkpoint binding and interaction assays to support your drug development project.

About Immune Checkpoints

Immune checkpoint proteins are surface molecules on immune effector cell populations that inhibit effector function when combined with their cognate ligands. Expression of these ligands on cancer cells has been suggested as a mechanism by which these cells evade the immune response. Therefore, therapeutics called immune checkpoint inhibitors that block interaction between the immune checkpoint protein and their ligands could restore the effector function of immune cells and promote tumor regression.

The clinical research of immune checkpoint proteins has achieved great success, making immunotherapy a promising method to treat cancer. Immune checkpoints are involved in a series of immunomodulatory pathways that can either co-stimulate or co-inhibit the immune response. Main immune checkpoints include programmed death-1 (PD-1), cytotoxic T lymphocyte antigen-4 (CTLA4), lymphocyte activation gene-3 (LAG3), and so on.

Current and emerging immune checkpoint receptors and their respective ligands. Fig.1 Current and emerging immune checkpoint receptors and their respective ligands. (Qin, 2019)

Binding and Interaction Assay Services

Creative Biolabs has been engaged in promoting immune checkpoint inhibitor development using our immuno-oncology assays for many years. We can offer a comprehensive set of binding and interaction assays to screen for promising candidates, proceed to interaction assays with selected candidates for blocking ability, and finally progress to functional assays that test for immuno-modulatory activity. With our customized project design, we can demonstrate your molecules' binding, interaction, and functional properties.

Current and emerging immune checkpoint receptors and their respective ligands. Fig.1 Current and emerging immune checkpoint receptors and their respective ligands. (Qin, 2019)

Features

  • Evaluate your immune checkpoint biologic or molecule for specific binding to the receptor using our innovative binding assay.
  • Binding affinities and binding inhibition can be generated with your molecules.
  • Personalized project design to ensure the most relevant data.
  • All assays are performed with high-quality reagents and strict controls by experienced immunologists.

Discover Your Molecules' Binding Properties

In conjunction with our immune checkpoint binding and interaction assays, Creative Biolabs can help to explore the binding and interaction properties of your molecule. Our tailored services will work with you to design a perfect technology solution to fulfill your program's scientific requirements. If you are interested in our assays, please contact us for more information.

Reference

  1. Qin, S.; et al. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4. Molecular cancer. 2019, 18(1): 1-14.

All listed customized services & products are for research use only, not intended for pharmaceutical, diagnostic, therapeutic, or any in vivo human use.